ATE386130T1 - Adenovirale vektoren für die gentherapie - Google Patents

Adenovirale vektoren für die gentherapie

Info

Publication number
ATE386130T1
ATE386130T1 AT96909800T AT96909800T ATE386130T1 AT E386130 T1 ATE386130 T1 AT E386130T1 AT 96909800 T AT96909800 T AT 96909800T AT 96909800 T AT96909800 T AT 96909800T AT E386130 T1 ATE386130 T1 AT E386130T1
Authority
AT
Austria
Prior art keywords
gene therapy
vectors
adenoviral vectors
adenovirus
novel
Prior art date
Application number
AT96909800T
Other languages
English (en)
Inventor
Donna Armentano
Helen Romanczuk
Samuel Wadsworth
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/409,874 external-priority patent/US5707618A/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE386130T1 publication Critical patent/ATE386130T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712Cystic fibrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96909800T 1995-03-24 1996-03-20 Adenovirale vektoren für die gentherapie ATE386130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/409,874 US5707618A (en) 1995-03-24 1995-03-24 Adenovirus vectors for gene therapy
US08/540,077 US5824544A (en) 1995-03-24 1995-10-06 Adenovirus vectors for gene therapy

Publications (1)

Publication Number Publication Date
ATE386130T1 true ATE386130T1 (de) 2008-03-15

Family

ID=27020791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909800T ATE386130T1 (de) 1995-03-24 1996-03-20 Adenovirale vektoren für die gentherapie

Country Status (8)

Country Link
EP (1) EP0843731B1 (de)
JP (1) JP3827163B2 (de)
AT (1) ATE386130T1 (de)
AU (1) AU718772B2 (de)
CA (1) CA2226833C (de)
DK (1) DK0843731T3 (de)
ES (1) ES2300105T3 (de)
WO (1) WO1996030534A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型gp100およびその使用
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2001090392A1 (en) * 2000-05-26 2001-11-29 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
DE10045687B4 (de) * 2000-09-15 2006-07-06 MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald Expressionskassetten und Adenovirusvektoren
US20030026783A1 (en) 2001-08-03 2003-02-06 Amine Abina Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
JP2007511211A (ja) 2003-11-14 2007-05-10 ホルム,ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
EP1831382B1 (de) 2004-12-31 2023-01-18 Per Sonne Holm Verfahren zur aufhebung von mehrfachresistenz in tierzellen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
SK283703B6 (sk) * 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
DE10234697A1 (de) 2002-07-30 2004-02-19 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens

Also Published As

Publication number Publication date
EP0843731B1 (de) 2008-02-13
DK0843731T3 (da) 2008-06-09
WO1996030534A1 (en) 1996-10-03
EP0843731A1 (de) 1998-05-27
CA2226833C (en) 2009-12-15
ES2300105T3 (es) 2008-06-01
AU5318496A (en) 1996-10-16
CA2226833A1 (en) 1996-10-03
JP3827163B2 (ja) 2006-09-27
AU718772B2 (en) 2000-04-20
JPH11506311A (ja) 1999-06-08

Similar Documents

Publication Publication Date Title
EP1923467A3 (de) Adenovirusvektoren für die Gentherapie
ATE386130T1 (de) Adenovirale vektoren für die gentherapie
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
DE60024302D1 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
FR2716682B1 (fr) Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
EP0841941A4 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
EP0935648A4 (de) Verbesserte adenovirusvektoren
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
AUPN477695A0 (en) Gene therapy
MXPA02002036A (es) Recombinacion especifica de la secuencia de adn en celulas eucarioticas.
ES8802160A1 (es) Un procedimiento para aislar un gen de relaxina cromosomica de un ser humano o de otro primate o una especie afin
ATE166109T1 (de) Methode zur genetischen veränderung von knochenmarkzellen von primaten und dafür brauchbare zellen, die rekombinante retrovirale vektoren produzieren
CY1105240T1 (el) 5’ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
CA2306449A1 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
FR2778670B1 (fr) Methodes et compositions pour la production de particules virales
ES2184059T3 (es) Vector retrovirico y su utilizacion en terapia genica.
FI971377A7 (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geen iä: itsemurha- ja immuunistimuloiva geeni
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
DE69535024D1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
EP0843006A3 (de) Rekombinante prostataspezifische Antigen-Vektoren und diese verwendende Assays

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0843731

Country of ref document: EP

REN Ceased due to non-payment of the annual fee